Mustang Bio, Inc.
MBIOHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeMustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating cell therapies into cures for difficult-to-treat cancers and autoimmune diseases in the United States. At a $4.7M market cap, Mustang Bio, Inc. ranks as a micro-cap company within healthcare. The company develops MB-106, a CD20-targeted chimeric antigen receptor (CAR) T cell therapy which is in Phase I clinical trail for non-hodgkin lymphoma, chronic lymphocytic leukemia, and autoimmune diseases; MB-109, a combination MB-101 and MB-108 as a potential treatment for IL13Ra2+ relapsed or refractory glioblastoma and high-grade astrocytoma; MB-101, an IL13Ra2 CAR T cell program completd Phase I for glioblastoma; and MB-108 which is in Phase I for the treatment of herpes simplex virus-1 oncolytic virus C134.
Market Cap
$4.7M
Beta
2.05
P/E (TTM)
—
P/E (Fwd)
-1.76
EPS (TTM)
$-0.45
EPS (Fwd)
$-0.35
ROE
-44.6%
ROA
-12.8%
Cash
$16.3M
Total Debt
$0
Free CF
-$4.9M
52W Change
-70.5%
Annual Financials
Cash vs Debt
Where MBIO stands vs its 150-day and 200-day moving averages
As of the July 15, 2026 close, MBIO finished 22.35% below its 150-day moving average ($0.85) and 33.33% below its 200-day moving average ($0.99). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is MBIO overbought or oversold?
At the July 15, 2026 close, MBIO's RSI(14) was 43.9, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Mustang Bio, Inc. reports $16.3M in cash and $0 in total debt. The company is burning cash, with free cash flow at -$4.9M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -44.6%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
With a beta above 1.5, MBIO tends to amplify broader market moves — both up and down. This higher volatility means larger price swings are common. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Mustang Bio, Inc.'s trajectory.